Novel tumor-suppressor gene epidermal growth factor‑containing fibulin‑like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer

Zhu,Xin-Jiang; Liu,Jian; Xu,Xiao-Yang; Zhang,Chun-Dong; Dai,Dong-Qiu

doi:10.3892/mmr.2014.2135

Novel tumor-suppressor gene epidermal growth factor‑containing fibulin‑like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer

Authors:
- Xin-Jiang Zhu
- Jian Liu
- Xiao-Yang Xu
- Chun-Dong Zhang
- Dong-Qiu Dai
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, Liaoning 110032, P.R. China
Published online on: April 9, 2014 https://doi.org/10.3892/mmr.2014.2135
Pages: 2283-2292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of histone modification and DNA methylation in epidermal growth factor‑containing fibulin‑like extracellular matrix protein 1 (EFEMP1) silencing in gastric cancer (GC). In the present study, four GC cell lines, and 45 paired normal and GC tissue samples were used to assess EFEMP1 expression using quantitative polymerase chain reaction (PCR), and EFEMP1 gene methylation status was evaluated by methylation‑specific PCR. The involvement of histone modification in GC cell lines was examined by a chromatin immunoprecipitation (ChIP) assay. The results demonstrated that EFEMP1 mRNA level and methylation status in the EFEMP1 promoter region was associated with tumor differentiation, depth of tumor invasion and lymph node metastasis. DNA methyltransferase inhibitor 5‑aza‑2'‑deoxycytidine (DAC) rapidly reduced DNA methylation and histone H3‑K9 trimethylation at the silenced loci and reactivated EFEMP1 expression. By contrast, the histone deacetylase inhibitor trichostatin A markedly increased histone H3‑K9 acetylation. However, it had no effect on DNA methylation, histone H3‑K9 trimethylation or gene expression. In conclusion, the results suggested that EFEMP1 may function as a tumor suppressor in GC. Aberrant DNA methylation and histone H3‑K9 trimethylation of EFEMP1 may be responsible for its downregulation in GC, and thus have an important role in tumor invasion and metastasis.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Allis CD, Berger SL, Cote J, et al: New nomenclature for chromatin-modifying enzymes. Cell. 131:633–636. 2007. View Article : Google Scholar : PubMed/NCBI
3	Cantone I and Fisher AG: Epigenetic programming and reprogramming during development. Nat Struct Mol Biol. 20:282–289. 2013. View Article : Google Scholar : PubMed/NCBI
4	Albig AR, Neil JR and Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
5	Yue W, Dacic S, Sun Q, et al: Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res. 13:4336–4344. 2007. View Article : Google Scholar : PubMed/NCBI
6	Nomoto S, Kanda M, Okamura Y, et al: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar
7	Kim YJ, Yoon HY, Kim SK, et al: EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 17:4523–4530. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sadr-Nabavi A, Ramser J, Volkmann J, et al: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 124:1727–1735. 2009. View Article : Google Scholar
9	Hwang CF, Chien CY, Huang SC, et al: Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol. 222:367–379. 2010. View Article : Google Scholar : PubMed/NCBI
10	En-lin S, Sheng-guo C and Hua-qiao W: The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol. 117:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
11	Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, et al: Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 15:535–544. 2011. View Article : Google Scholar : PubMed/NCBI
12	Seeliger H, Camaj P, Ischenko I, et al: EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
13	Fahrner JA, Eguchi S, Herman JG and Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62:7213–7218. 2002.PubMed/NCBI
14	Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 21:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
15	Kuo MH and Allis CD: In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. Methods. 19:425–433. 1999. View Article : Google Scholar : PubMed/NCBI
16	Wang R, Zhang YW and Chen LB: Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer. 69:239–244. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
18	Meng CF, Zhu XJ, Peng G and Dai DQ: Role of histone modifications and DNA methylation in the regulation of O⁶-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells. Cancer Invest. 28:331–339. 2010. View Article : Google Scholar : PubMed/NCBI
19	Meng CF, Zhu XJ, Peng G and Dai DQ: Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol Rep. 22:1221–1227. 2009.PubMed/NCBI
20	Chang X, Zhang S, Ma J, et al: Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens. Cell Biochem Biophys. 66:93–101. 2013. View Article : Google Scholar : PubMed/NCBI
21	Grewal SI and Moazed D: Heterochromatin and epigenetic control of gene expression. Science. 301:798–802. 2003. View Article : Google Scholar : PubMed/NCBI
22	Peters AH, Mermoud JE, O’Carroll D, et al: Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet. 30:77–80. 2002. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y and Marmorstein LY: Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res. 90:374–375. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hu Y, Pioli PD, Siegel E, et al: EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 10:1232011. View Article : Google Scholar : PubMed/NCBI
25	Kim EJ, Lee SY, Woo MK, et al: Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol. 40:402–408. 2012.PubMed/NCBI
26	Tong JD, Jiao NL, Wang YX, Zhang YW and Han F: Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma. 58:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yang T, Qiu H, Bao W, et al: Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma. PLoS One. 8:e674582013. View Article : Google Scholar : PubMed/NCBI
28	Jaenisch R and Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 33(Suppl): 245–254. 2003. View Article : Google Scholar : PubMed/NCBI
29	Nawrocki ST, Carew JS, Douglas L, et al: Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 67:6987–6994. 2007. View Article : Google Scholar : PubMed/NCBI
30	Chang X, Li Z, Ma J, et al: DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci. 58:715–723. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhi Y, Chen J, Zhang S, et al: Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci. 57:650–659. 2012. View Article : Google Scholar : PubMed/NCBI
32	Fuks F, Hurd PJ, Deplus R and Kouzarides T: The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31:2305–2312. 2003. View Article : Google Scholar : PubMed/NCBI
33	Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y and Futscher BW: 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 26:77–90. 2007.
34	Lin W and Dent SY: Functions of histone-modifying enzymes in development. Curr Opin Genet Dev. 16:137–142. 2006. View Article : Google Scholar
35	Martin C and Zhang Y: The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 6:838–849. 2005. View Article : Google Scholar : PubMed/NCBI
36	Hu Q, Yu L, Chen R, et al: 5-aza-2′-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Int J Gynecol Cancer. 22:951–959. 2012.